The development of innovative biosensing technologies for the early detection of prostate cancer has garnered significant attention in recent years. Among these technologies, portable Amperometric biosensors have shown immense promise due to their sensitivity, specificity, portability, and rapid response times. The integration of enzyme-based ternary nanocomposites into these biosensors represents a groundbreaking advancement, offering enhanced detection capabilities for prostate cancer biomarkers. This discussion explores the principles, design, and advantages of these biosensors, along with their potential for revolutionizing prostate cancer diagnostics. Prostatespecific antigen is the most widely used biomarker for detecting prostate cancer. Elevated PSA levels in blood serum are often indicative of the presence or progression of the disease. While conventional methods such as enzymelinked immunosorbent assays are effective for PSA detection, they are often time-consuming, expensive, and require specialized laboratory equipment. In contrast, Amperometric biosensors provide a faster, cost-effective, and portable alternative, enabling point-of-care testing and real-time monitoring. The integration of enzyme-based ternary nanocomposites into the biosensor architecture significantly enhances its performance, addressing key challenges in biomarker detection.
HTML PDFShare this article
Biosensors & Bioelectronics received 6207 citations as per Google Scholar report
